Urology · Crestview Hills, KY
NPI
1881919744
Since 2010
Specialty
Urology
Code 208800000X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
350 Thomas More Pkwy, Suite 200
Crestview Hills, KY, 41017
Phone (859) 363-2200
Groups this clinician bills Medicare through
Medicare paid, 2024
$437K
18,530 services
Medicare patients, 2024
563
Average age 74
Drug cost, 2024
$5.8M
2,553 prescriptions
Company payments, 2025
$2,539
From 28 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Robert J Larke was code J0897 (injection, denosumab, 1 mg), 5,040 times for 39 patients. In total Robert J Larke billed 18,530 services in 103 codes, and Medicare paid $437K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-07-14.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 5,040 | 39 | $19.59 | $99K |
| J1952 Leuprolide injectable, camcevi, 1 mg | Office | 2,730 | 39 | $44.29 | $121K |
| J9155 Injection, degarelix, 1 mg | Office | 2,640 | 11 | $3.27 | $8,636 |
| J9030 Bcg live intravesical instillation, 1 mg | Office | 2,500 | 21 | $2.27 | $5,670 |
| 81002 Clinical Chemistry | Office | 720 | 397 | $3.38 | $2,437 |
| 99214 Office E&M - Established | Office | 693 | 372 | $87.92 | $61K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 589 | 380 | $11.30 | $6,653 |
| 84153 Clinical Chemistry | Office | 393 | 221 | $17.76 | $6,979 |
| 36415 Venipuncture Blood Collection | Office | 339 | 177 | $8.58 | $2,908 |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 261 | 56 | $49.77 | $13K |
| 84403 Clinical Chemistry | Office | 162 | 58 | $24.40 | $3,953 |
| 51798 Ultrasound - Nonspecific | Office | 118 | 90 | $7.84 | $925 |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 105 | 40 | $38.97 | $4,091 |
| 80053 Clinical Chemistry | Office | 101 | 32 | $10.35 | $1,045 |
| 96402 Chemotherapy Administration | Office | 92 | 50 | $26.37 | $2,426 |
By year: 2022 $287K for 13,127 services; 2023 $357K for 13,252 services; 2024 $437K for 18,530 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81002 Clinical Chemistry | 720 | 397 | $3.38 | $2,437 |
| 84153 Clinical Chemistry | 393 | 221 | $17.76 | $6,979 |
| 36415 Venipuncture Blood Collection | 339 | 177 | $8.58 | $2,908 |
| 84403 Clinical Chemistry | 162 | 58 | $24.40 | $3,953 |
| 80053 Clinical Chemistry | 101 | 32 | $10.35 | $1,045 |
| 84154 Clinical Chemistry | 72 | 59 | $18.02 | $1,297 |
| 86316 Immunoassay | 70 | 57 | $20.39 | $1,427 |
| 82310 Clinical Chemistry | 60 | 29 | $4.66 | $280 |
| 82565 Clinical Chemistry | 36 | 35 | $5.02 | $181 |
| 87086 Bacterial Culture | 33 | 29 | $7.91 | $261 |
Medicare prescription drug claims, 2024
In 2024, the drug Robert J Larke prescribed most often to Medicare patients was Tamsulosin Hcl, with 559 prescriptions and refills. In total Robert J Larke wrote 2,553 Medicare prescriptions that cost $5.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tamsulosin Hcl Generic | 559 | 1,453 | 179 | $6,279 |
| Abiraterone Acetate Generic | 346 | 358 | 40 | $815K |
| Finasteride Generic | 344 | 988 | 108 | $4,079 |
| Prednisone Generic | 302 | 354 | 39 | $1,204 |
| Xtandi Enzalutamide | 213 | 213 | 24 | $2.8M |
| Orgovyx Relugolix | 117 | 117 | 14 | $312K |
| Nubeqa Darolutamide | 75 | 75 | Under 11 | $956K |
| Cephalexin Generic | 64 | 107 | 37 | $382 |
| Myrbetriq Mirabegron | 62 | 126 | 20 | $56K |
| Erleada Apalutamide | 34 | 34 | Under 11 | $426K |
| Ciprofloxacin Hcl Generic | 34 | 34 | 32 | $188 |
| Silodosin Generic | 31 | 93 | Under 11 | $3,414 |
| Oxybutynin Chloride Er Oxybutynin Chloride | 24 | 44 | Under 11 | $500 |
| Nitrofurantoin Nitrofurantoin Macrocrystal | 23 | 43 | Under 11 | $410 |
| Eligard Leuprolide Acetate | 21 | 119 | 13 | $53K |
Brand drugs: 606 claims; generic drugs: 1,947 claims; opioid claims: 28.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Robert J Larke $2,539 ($2,539 in general payments such as food, travel and fees) from 28 companies. The largest payer was Calyxo, Inc. with $461.
| Company | Payments | Amount |
|---|---|---|
| Calyxo, Inc. | 4 | $461 |
| Boston Scientific Corporation BSX | 4 | $168 |
| Sumitomo Pharma America, Inc. 4506.T | 8 | $167 |
| Astellas Pharma US Inc 4503.T | 7 | $159 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 6 | $147 |
| Dendreon Pharmaceuticals LLC | 4 | $143 |
| Novartis Pharmaceuticals Corporation NVS | 5 | $137 |
| Endo USA, Inc. | 2 | $136 |
| Janssen Scientific Affairs, LLC JNJ | 1 | $124 |
| Olympus America Inc. | 6 | $123 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.